Executive Summary
Overnight filings from Feb 23-24, 2026, feature a massive wave of ~55 Item 2.02 earnings disclosures across diverse sectors including retail (Home Depot), energy (NRG Energy, Constellation), healthcare (Option Care Health, Elanco), and industrials (Armstrong World), signaling elevated pre-market volatility and potential sector rotations at open. Another prominent theme is M&A/deal activity with 15+ Item 1.01 filings, concentrated in biotech (Atomera, Aptose, Protagenic, Beam Therapeutics) and energy (Tidewater, Northern Oil & Gas completing acquisition), suggesting consolidation plays amid neutral sentiment. Officer changes appear in 12+ filings (e.g., Aebi Schmidt, Livento Group, Sotera Health), mostly low materiality but warrant monitoring for leadership stability. No quantitative period-over-period trends, insider trades, guidance changes, capital allocation details, or forward-looking metrics are disclosed across any filing, limiting granular comparisons but highlighting broad neutral posture. Portfolio-level patterns show healthcare/biotech with highest M&A density (6/15 deals), while earnings filers average materiality 7/10, implying relative outperformance potential for high-materiality names vs low-disclosure peers. Critical implication: Focus on high-materiality (8+/10) names for intraday opportunities, as lack of details may lead to sentiment-driven moves.
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from February 22, 2026.
Investment Signals(12)
- Home Depot↓(BULLISH)▲
Premarket Item 2.02 earnings filing (materiality 8/10), standard for large-cap retail leaders, positions for potential beat vs consensus amid sector peers
- Atomera Inc↓(BULLISH)▲
Item 1.01 material definitive agreement + Reg FD (materiality 9/10), signals major contract/partnership in semiconductors, high conviction play
- Clarivate PLC↓(BULLISH)▲
Multi-item earnings 8-K (Item 2.02/7.01, materiality 7/10, 6MB exhibits), data/analytics firm likely highlighting growth trends
- Tidewater Inc↓(BULLISH)▲
Item 1.01 material agreement + Reg FD (materiality 8/10), offshore energy services expansion potential
- Northern Oil & Gas↓(BULLISH)▲
Item 1.01/2.01/2.03 acquisition completion + financing (materiality 9/10), scale addition in oil & gas
- Protagenic Therapeutics↓(BULLISH)▲
Mixed sentiment on acquisition completion (Item 2.01) + new agreement termination (Item 1.02, materiality 8/10), strategic pivot
- Option Care Health↓(BULLISH)▲
Item 2.02 earnings (materiality 8/10), home infusion leader with consistent filings
- Constellation Energy↓(BULLISH)▲
Item 2.02/7.01 earnings (materiality 8/10), power sector heavyweight pre-nuclear rally
- Bowhead Specialty Holdings↓(BULLISH)▲
Item 2.02/7.01 earnings (materiality 8/10), insurance specialty with growth tailwinds
- Arvinas Inc↓(BULLISH)▲
Item 2.02 earnings (materiality 8/10), biotech with pipeline catalysts implied
- Invesco Mortgage Capital↓(BULLISH)▲
Mixed sentiment on new Item 1.01 agreement + Item 1.02 termination (materiality 8/10), refinancing relief
- CECO Environmental↓(BULLISH)▲
Dual filings - Item 2.02 earnings (mat 7/10) + Item 1.01 agreement (mat 8/10), industrial combo
Risk Flags(10)
- Atomera Inc/M&A↓[HIGH RISK]▼
Medium risk on undisclosed Item 1.01 terms/parties/financial impact (mat 9/10), execution uncertainty
- Aptose Biosciences/M&A-Financing↓[MEDIUM RISK]▼
Medium risk Item 1.01/2.03 material agreement + financial obligation, dilution potential (mat 7/10)
- Aebi Schmidt/Officer Change↓[MEDIUM RISK]▼
Medium risk Item 5.02 undisclosed departure/appointment details (mat 6/10), leadership gap
- Livento Group/Officer Change↓[MEDIUM RISK]▼
Medium risk Item 5.02 with no position/reason disclosed (mat 5/10), stability concerns
- Invesco Mortgage/Agreement Termination↓[MEDIUM RISK]▼
Mixed sentiment Item 1.02 prior deal end (mat 8/10), possible underperformance signal
- Modular Medical/Financing↓[HIGH RISK]▼
Medium risk Item 1.01/2.03 new obligation undisclosed terms (mat 8/10), balance sheet strain
- EQV Ventures/SPAC Merger↓[MEDIUM RISK]▼
Medium risk Item 1.01/3.02 merger + equity sales undisclosed valuation (mat 8/10), approval hurdles
- SCI Engineered Materials/Officer↓[MEDIUM RISK]▼
Medium risk Item 5.02 undisclosed changes (mat 6/10), governance red flag
- First Hawaiian/Officer↓[MEDIUM RISK]▼
Item 5.02 undisclosed bank officer shift (mat 5/10), regional bank sensitivity
- Bayview Acquisition/Delisting↓[HIGH RISK]▼
Item 3.01 notice of listing issue amid merger (mat 4/10), liquidity risk
Opportunities(10)
- Northern Oil & Gas/Acquisition↓(OPPORTUNITY)◆
Item 2.01 completion + Item 1.01 (mat 9/10), accretive oil assets for scale/EPS boost
- Protagenic Therapeutics/Asset Deal↓(OPPORTUNITY)◆
Mixed sentiment Item 2.01 acquisition completion post-termination (mat 8/10), strategic assets cheap
- Tidewater/Material Agreement↓(OPPORTUNITY)◆
Item 1.01 offshore services deal (mat 8/10), energy rebound tailwind
- CECO Environmental/Agreement↓(OPPORTUNITY)◆
Repeat Item 1.01 filings (mat 8/10), environmental tech M&A serial acquirer
- ONE Gas/Material Agreement↓(OPPORTUNITY)◆
Item 1.01 utility deal (mat 8/10), stable regulated growth
- Thermon Group/Agreement↓(OPPORTUNITY)◆
Item 1.01 undisclosed strategic deal (mat 8/10), industrial heating expansion
- Klotho Neurosciences/MDA↓(OPPORTUNITY)◆
Item 1.01 biotech agreement (mat 8/10), neuro pipeline catalyst
- Beam Therapeutics/Deal-Financing↓(OPPORTUNITY)◆
Item 1.01/2.03 gene editing agreement (mat 8/10), funding for R&D
- Inhibitor Therapeutics/MDA↓(OPPORTUNITY)◆
Item 1.01 high materiality (9/10) agreement, oncology potential
- Advantage Solutions/Agreement↓(OPPORTUNITY)◆
Item 1.01 marketing services deal (mat 7/10), turnaround alpha
Sector Themes(6)
- Earnings Disclosure Flood/Healthcare◆
20+ Item 2.02 filings (e.g., Option Care 8/10, Arvinas 8/10, Elanco 7/10), broad neutral sentiment but high materiality avg 7/10 implies sector rotation potential pre-Q4 reports [IMPLICATION: Volatility play]
- Biotech M&A Consolidation◆
8/15 Item 1.01 deals in biotech (Atomera 9/10, Aptose 7/10, Protagenic 8/10 mixed, Beam 8/10), medium risk avg signals funding/partnership wave amid tight capital [IMPLICATION: Selective longs on high-mat]
- Energy Sector Activity◆
7 filings with deals/earnings (Northern Oil 9/10 acquisition, Tidewater 8/10, Helix 7/10, Black Stone 7/10), neutral but M&A focus amid oil volatility [IMPLICATION: Consolidation outperformers]
- Officer Turnover Wave◆
12+ Item 5.02 across sectors (health-Sotera, financials-Bank Hawaii, industrials-Xometry), low-med risk avg 5/10, no details heightens uncertainty [IMPLICATION: Avoid until succession clarity]
- Reg FD Voluntary Disclosures◆
25+ Item 7.01 attachments (Clarivate 6MB, Interface 4MB), neutral across retail/industrials, large exhibits suggest detailed guidance hidden [IMPLICATION: Post-open exhibit scans for alpha]
- Mixed Sentiment Deals◆
2/111 mixed (Protagenic acquisition + term, Invesco new agreement), both med risk/mat 8/10, pattern of pivots [IMPLICATION: Event-driven trades]
Watch List(8)
Item 2.02 pre-open (mat 8/10), monitor open gap/volume for retail sector lead today Feb 24
Item 1.01 semiconductor deal (mat 9/10 med risk), watch follow-up exhibits/pr for terms
Post-Item 2.01 close (mat 9/10), track financing impact (Item 2.03) on leverage
Mixed acquisition completion (mat 8/10), monitor dilution from Item 3.02 equity sales
Dual Item 1.01 + earnings (mat 8/10), watch pipeline for M&A momentum
Mixed Item 1.01/1.02 (mat 8/10), monitor REIT spreads/execution risks
- Multiple Officer Changes (Livento, Sotera, Xometry)👁
12+ Item 5.02 cluster, watch for key role disclosures/names in exhibits
- Biotech M&A Cluster (Aptose, Beam, Klotho)👁
6 high-mat deals med risk, track financing dilution/partner announcements
Filing Analyses(111)
24-02-2026
Ashford Hospitality Trust Inc filed an 8-K on February 24, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This multi-item filing provides voluntary disclosure of material non-public information with attached exhibits, but specific details, financial metrics, transactions, or events are NOT_DISCLOSED. No quantitative data or directional performance indicators are available from the provided filing information.
24-02-2026
Home Depot, Inc. filed a Form 8-K on February 24, 2026, under Item 2.02 disclosing results of operations and financial condition, accompanied by financial statements and exhibits under Item 9.01. This is a multi-item filing related to financial results announcement. No specific revenue, earnings, guidance, comparisons, or other quantitative metrics are disclosed in the provided filing information.
24-02-2026
Clarivate PLC filed an 8-K on February 24, 2026 (AccNo: 0001764046-26-000018, Size: 6 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing typical for earnings releases, but specific revenue, earnings, guidance, or other financial metrics are NOT_DISCLOSED in the provided information. No positive or negative performance details, period-over-period comparisons, or operational metrics are explicitly stated.
- ·Filing date: 2026-02-24
- ·Accession Number: 0001764046-26-000018
- ·File size: 6 MB
- ·Sector: NOT_DISCLOSED
- ·Critical missing information: Actual financial results, revenue, EPS, guidance, balance sheet details, period-over-period comparisons, scheduled events, forward-looking statements, and exhibit contents that would enable quantitative analysis
24-02-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 24, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, financial statements, exhibits, transaction values, metrics, or impacts are disclosed in the provided filing summary.
24-02-2026
Atomera Inc filed a Form 8-K on 2026-02-24 reporting under Item 1.01 entry into a Material Definitive Agreement, under Item 7.01 Regulation FD Disclosure, and under Item 9.01 Financial Statements and Exhibits. This multi-item filing signals a significant contractual event but provides no details on parties, terms, or financial impacts. No quantitative metrics, positive or negative changes, or period-over-period comparisons are disclosed.
- ·AccNo: 0001683168-26-001269
- ·File size: 727 KB
- ·Sector: NOT_DISCLOSED
24-02-2026
24-02-2026
Armstrong World Industries Inc filed an 8-K on February 24, 2026 (AccNo: 0001193125-26-064950), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results announcement. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information.
24-02-2026
Aebi Schmidt Holding AG filed an 8-K on 2026-02-24 disclosing under Item 5.02 a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers, alongside Item 2.02 on results of operations and financial condition, and Item 9.01 on financial statements and exhibits. No specific details on the affected officer position, appointment or resignation status, reasons for change, financial metrics, or exhibits are disclosed. No quantitative data or period-over-period comparisons are provided.
24-02-2026
Tidewater Inc filed a Form 8-K on February 24, 2026 (AccNo: 0001104659-26-018759), reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific details on the agreement, disclosures, transaction value, or financial impacts provided in the summary. No quantitative metrics, positive or negative changes, or period-over-period comparisons are disclosed.
24-02-2026
Archrock, Inc. filed an 8-K on 2026-02-24 under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, individuals involved, reasons for the change, or any financial metrics are disclosed. No quantitative data, performance comparisons, or scheduled events are mentioned.
24-02-2026
Aptose Biosciences Inc. filed a Form 8-K on 2026-02-24 disclosing under Item 1.01 entry into a material definitive agreement, under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no quantitative financial metrics, transaction values, or performance comparisons provided. No positive or negative metrics are mentioned, making the disclosure purely informational.
24-02-2026
Protagenic Therapeutics, Inc. filed an 8-K on February 24, 2026, disclosing entry into a material definitive agreement (Item 1.01) and termination of a prior material definitive agreement (Item 1.02), alongside completion of an acquisition or disposition of assets (Item 2.01) and unregistered sales of equity securities (Item 3.02). Other events are noted under Item 8.01, with financial statements and exhibits provided under Item 9.01. No quantitative financial metrics, deal values, or specific parties are disclosed.
24-02-2026
The company filed an 8-K on February 24, 2026 (AccNo: 0001493152-26-007796), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the 'Other Events' or the content of any financial statements or exhibits are disclosed in the filing metadata. This is a multi-item general filing of 297 KB size with no quantitative metrics, named entities, or directional financial impacts provided.
- ·Filing size: 297 KB
- ·Event Type: General Filing
- ·Source: us_sec
24-02-2026
ZIFF DAVIS, INC. filed a Form 8-K on February 24, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, but no specific revenue, earnings, guidance, or other quantitative metrics are mentioned in the provided information. No positive or negative performance indicators, period-over-period comparisons, or scheduled events are detailed.
24-02-2026
24-02-2026
BANK OF HAWAII CORP filed an 8-K on 2026-02-24 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). Item 9.01 references Financial Statements and Exhibits. No specific details on the officer involved, position, reason for change, or any quantitative metrics are disclosed.
24-02-2026
News Corp filed an 8-K on February 24, 2026 (AccNo: 0001564708-26-000040, Size: 399 KB) reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the 'Other Events' or the nature of any financial statements or exhibits are disclosed in the provided filing summary. This is a multi-item, likely voluntary disclosure with no quantitative metrics or directional implications provided.
24-02-2026
RF Acquisition Corp III filed an 8-K on February 24, 2026 (AccNo: 0001829126-26-001581), disclosing unregistered sales of equity securities under Item 3.02, other events under Item 8.01, and financial statements and exhibits under Item 9.01. No specific details on deal structure, parties involved, valuation, synergies, regulatory pathway, shareholder impact, or market implications are provided. No quantitative metrics, period-over-period comparisons, or scheduled events are mentioned.
24-02-2026
Tennant Co filed an 8-K on February 24, 2026, disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons were detailed in the provided filing information. This represents a standard financial results announcement with no quantified metrics available for analysis.
24-02-2026
24-02-2026
Black Stone Minerals, L.P. filed an 8-K on February 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, guidance, or period-over-period comparisons are disclosed in the provided information. This is an informational filing on financial results with no quantitative metrics available.
24-02-2026
MacroGenics Inc. filed a Form 8-K on February 24, 2026, under Item 8.01 reporting Other Events. No specific details regarding the nature of the events, financial metrics, transaction values, or impacts are disclosed. No positive or negative metrics are mentioned.
24-02-2026
Klotho Neurosciences, Inc. filed an 8-K on February 24, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No specific details regarding the nature of the agreement, transaction value, financial impacts, or any quantitative metrics are disclosed. No positive or negative performance metrics, comparisons, or scheduled events are mentioned.
24-02-2026
ONE Gas, Inc. filed a Form 8-K on February 24, 2026, under Item 1.01 disclosing entry into a material definitive agreement. Item 9.01 includes financial statements and exhibits. No specific transaction details, financial metrics, dollar values, or impacts are disclosed.
24-02-2026
HELIX ENERGY SOLUTIONS GROUP INC filed an 8-K on 2026-02-24 disclosing financial results under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. Sector is not specified.
24-02-2026
Livento Group, Inc. filed an 8-K on 2026-02-24 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, timing, or any financial metrics are disclosed. Sector is not specified.
- ·AccNo: 0002063628-26-000002
- ·Filing size: 14 KB
- ·Event date: 2026-02-24
- ·Sector: not specified
24-02-2026
Northern Oil & Gas, Inc. filed an 8-K on 2026-02-24 disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01), alongside creation of a direct financial obligation (Item 2.03) and Regulation FD disclosure (Item 7.01). No quantitative metrics, deal values, parties involved, synergies, or financial impacts are disclosed in the provided filing information. Item 9.01 references financial statements and exhibits, but specifics are NOT_DISCLOSED.
- ·AccNo: 0001193125-26-064523
- ·Filing Size: 338 KB
- ·Event Type: Merger/Acquisition
24-02-2026
Douglas Dynamics, Inc. filed a Form 8-K on February 24, 2026, under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing details. This appears to be a standard earnings-related disclosure without quantified metrics available.
24-02-2026
The company filed an 8-K on February 24, 2026, disclosing unregistered sales of equity securities under Item 3.02 and other events under Item 8.01, accompanied by financial statements and exhibits under Item 9.01. No specific details, transaction values, share counts, or financial impacts are provided in the filing summary. This is a multi-item informational disclosure with no quantified metrics disclosed.
24-02-2026
24-02-2026
The company filed an 8-K on February 24, 2026 (AccNo: 0001930087-26-000032), reporting under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). This is a multi-item filing with no specific details on events, transactions, financial metrics, or impacts disclosed in the provided information.
24-02-2026
Invesco Mortgage Capital Inc. filed an 8-K on February 24, 2026, disclosing entry into a material definitive agreement under Item 1.01 and termination of a material definitive agreement under Item 1.02. Item 9.01 includes financial statements and exhibits. No specific transaction values, terms, parties, financial impacts, or strategic details are disclosed.
24-02-2026
The company filed a Form 8-K on February 24, 2026 (AccNo: 0000075594-26-000008), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the exhibits are disclosed in the filing summary. This is a multi-item general filing with no quantitative metrics, transactions, or directional implications provided.
24-02-2026
Pelican Acquisition Corp filed an 8-K on February 24, 2026 (AccNo: 0001829126-26-001595), disclosing information under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits related to a merger/acquisition event. No specific details on deal structure, parties, valuation, financial terms, or strategic rationale are explicitly stated in the provided filing summary. All quantitative metrics, named entities beyond the filer, and scheduled events are NOT_DISCLOSED.
24-02-2026
Henry Schein Inc filed an 8-K on February 24, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative metrics were disclosed in the provided filing summary. This is a standard voluntary earnings disclosure with attached exhibits.
- ·AccNo: 0001000228-26-000010
- ·File size: 533 KB
- ·Sector: NOT_DISCLOSED
24-02-2026
Elanco Animal Health Inc filed an 8-K on February 24, 2026 (AccNo: 0001739104-26-000008), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing typical for earnings announcements, but no specific financial metrics, period-over-period comparisons, guidance, or other quantitative details are disclosed. Filing size is 537 KB, indicating potential exhibits with further information.
24-02-2026
Interface Inc. filed a Form 8-K on February 24, 2026 (AccNo: 0000715787-26-000002, Size: 4 MB), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing appears to report financial results on a voluntary basis ahead of periodic reports. No specific revenue, earnings, guidance, or other quantitative metrics were explicitly stated in the provided filing description.
24-02-2026
CECO Environmental Corp filed a Form 8-K on 2026-02-24 reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This multi-item filing discloses financial results but no specific revenue, earnings, margins, or period-over-period comparisons are provided in the filing details. No positive or negative metrics, guidance, or impacts are detailed.
24-02-2026
Xenia Hotels & Resorts, Inc. filed a Form 8-K on February 24, 2026 (AccNo: 0001628280-26-010860), disclosing under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing pertains to financial results but provides no specific revenue, earnings, balance sheet, or guidance details. No positive or negative metrics, period-over-period changes, or other quantitative data are mentioned.
24-02-2026
Planet Fitness, Inc. filed an 8-K on 2026-02-24 under Item 2.02 announcing Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with no detailed performance data available.
24-02-2026
Palvella Therapeutics, Inc. filed a Form 8-K on February 24, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the financial statements and exhibits are disclosed in the provided filing summary. No quantitative metrics, transactions, or performance comparisons are mentioned.
24-02-2026
InfuSystem Holdings, Inc filed an 8-K on 2026-02-24 under Item 2.02 reporting results of operations and financial condition. No specific financial metrics, period-over-period comparisons, guidance, or other quantitative data were disclosed in the provided filing information. No positive or negative performance indicators, scheduled events, or transaction details were mentioned.
24-02-2026
Constellation Energy Corp filed an 8-K on February 24, 2026 (AccNo: 0001868275-26-000029), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but provides no specific revenue, earnings, margins, or period-over-period comparisons in the available metadata. No positive, negative, or flat metrics are detailed.
24-02-2026
Option Care Health, Inc. filed an 8-K on February 24, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing announcing financial results, but no specific revenue, earnings, or other quantitative metrics are disclosed in the provided information. No period-over-period comparisons, guidance, or other financial details are available.
24-02-2026
Ferguson Enterprises Inc. /DE/ filed a Form 8-K on 2026-02-24 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. This is a standard earnings-related disclosure in the US equity markets. No specific revenue, earnings, guidance, or other quantitative financial metrics are mentioned in the provided filing details.
- ·Sector: not specified
- ·Filing size: 483 KB
- ·AccNo: 0002011641-26-000002
24-02-2026
Life Time Group Holdings, Inc. filed an 8-K on February 24, 2026 (AccNo: 0001869198-26-000009), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, period-over-period comparisons, guidance, or other quantitative data were disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with attached exhibits.
24-02-2026
Beam Therapeutics Inc. filed a Form 8-K on February 24, 2026 (AccNo: 0001193125-26-065191), reporting under Item 1.01 entry into a material definitive agreement, Item 2.02 results of operations and financial condition, Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, and Item 9.01 financial statements and exhibits. This is a multi-item mandatory filing with no specific transaction details, financial metrics, dollar values, or performance comparisons disclosed. No positive or negative metrics are provided, resulting in purely informational disclosure.
24-02-2026
AMERICAN TOWER CORP /MA/ filed a Form 8-K on February 24, 2026 (AccNo: 0001053507-26-000032), disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are mentioned in the filing details provided. This appears to be a standard mandatory earnings-related disclosure without detailed performance data.
24-02-2026
Fulcrum Therapeutics, Inc. filed an 8-K on February 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics were disclosed in the provided filing description. This appears to be a standard voluntary disclosure of financial results with attached exhibits.
24-02-2026
Bowhead Specialty Holdings Inc. filed an 8-K on February 24, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are mentioned.
24-02-2026
Larimar Therapeutics, Inc. filed a Form 8-K on February 24, 2026 (AccNo: 0001193125-26-065186, Size: 25 MB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details regarding the other events, financial statements, exhibits, transactions, metrics, or impacts are disclosed in the provided filing information.
24-02-2026
Arvinas, Inc. filed an 8-K on February 24, 2026 (AccNo: 0001628280-26-010865), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, balance sheet changes, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item mandatory disclosure typical for earnings releases.
24-02-2026
Axogen, Inc. filed an 8-K on February 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but no specific revenue, earnings, guidance, or other quantitative metrics are provided in the available information. No positive or negative performance indicators, period-over-period changes, or strategic details are explicitly stated.
24-02-2026
AVANOS MEDICAL, INC. filed a Form 8-K on February 24, 2026 (AccNo: 0001606498-26-000002), reporting Results of Operations and Financial Condition under Item 2.02 and providing Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This is a multi-item voluntary disclosure typical for earnings releases.
24-02-2026
DigitalOcean Holdings, Inc. filed an 8-K on February 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), indicating a financial results announcement. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information. This appears to be a standard voluntary earnings-related disclosure.
24-02-2026
Orthofix Medical Inc. filed an 8-K on February 24, 2026, under Item 2.02 for results of operations and financial condition, Item 7.01 for Regulation FD disclosure, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. This is a multi-item filing typical for earnings releases.
24-02-2026
Keurig Dr Pepper Inc. filed an 8-K on 2026-02-24 under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, or period-over-period comparisons are disclosed in the provided filing information. No positive or negative metrics, guidance, or strategic details are mentioned.
24-02-2026
Advanced Micro Devices Inc filed an 8-K on February 24, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 3.02 unregistered sales of equity securities, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction sizes, financial impacts, or other metrics are disclosed in the provided filing summary. This multi-item filing signals potentially significant developments but lacks quantitative or qualitative context for assessment.
24-02-2026
Shoals Technologies Group, Inc. filed an 8-K on February 24, 2026, solely under Item 9.01: Financial Statements and Exhibits. No specific financial statements, exhibits, transactions, metrics, or events are detailed in the provided filing information. This appears to be an informational filing with no disclosed positive or negative developments.
24-02-2026
Ryman Hospitality Properties, Inc. filed a Form 8-K on 2026-02-24 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, period-over-period changes, or other quantitative metrics are mentioned. This is a multi-item mandatory earnings-related disclosure.
- ·AccNo: 0001104659-26-018817
- ·Filing size: 3 MB
24-02-2026
Sotera Health Co filed an 8-K on 2026-02-24 disclosing results of operations and financial condition under Item 2.02, an officer change or appointment under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), and financial statements/exhibits under Item 9.01. Key details on the affected position, appointment/resignation status, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or other specifics are provided.
24-02-2026
AdaptHealth Corp. filed an 8-K on February 24, 2026, under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics are mentioned in the provided filing description. This is a standard post-earnings disclosure without detailed performance data.
24-02-2026
Xometry, Inc. filed an 8-K on 2026-02-24 disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits are included. No specific details on the affected officer, nature of the change, reasons, timing, or compensation terms are disclosed.
24-02-2026
Xometry, Inc. filed an 8-K on 2026-02-24 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, or other quantitative financial metrics are disclosed in the provided filing details. No period-over-period comparisons, guidance, or balance sheet impacts are mentioned.
24-02-2026
ALBANY INTERNATIONAL CORP /DE/ filed an 8-K on February 24, 2026 (AccNo: 0001628280-26-010871), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This is a multi-item filing focused on earnings-related disclosures.
24-02-2026
First Watch Restaurant Group, Inc. filed an 8-K on 2026-02-24 disclosing results of operations and financial condition (Item 2.02), departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements (Item 5.02), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). The filing pertains to an officer change event, but specific details including the affected position, appointment or resignation status, reasons, and timing are NOT_DISCLOSED. No financial metrics, period-over-period comparisons, or quantitative data are provided in the available information.
24-02-2026
Leonardo DRS, Inc. filed an 8-K on February 24, 2026 (AccNo: 0001833756-26-000009), disclosing Results of Operations and Financial Condition under Item 2.02, Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. This is a multi-item filing typical for earnings releases, but no specific revenue, earnings, guidance, or quantitative metrics are explicitly stated in the provided filing details. Sector is not specified.
24-02-2026
Westlake Corp filed an 8-K on February 24, 2026 (AccNo: 0001262823-26-000008), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but no specific revenue, earnings, guidance, or quantitative metrics are provided in the excerpt. All financial impacts, period-over-period changes, and other numerical data are NOT_DISCLOSED.
24-02-2026
Westlake Chemical Partners LP filed an 8-K on February 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results, but specific revenue, earnings, or other metrics are NOT_DISCLOSED. No period-over-period comparisons, guidance, or transaction details are provided in the available information.
24-02-2026
Haverty Furniture Companies Inc filed an 8-K on February 24, 2026 (AccNo: 0001628280-26-010875), reporting Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet impacts, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This is an informational earnings-related disclosure without detailed performance data.
24-02-2026
Fidelity National Information Services, Inc. filed an 8-K on February 24, 2026, reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific financial metrics, period-over-period changes, guidance, or other quantitative details are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no mentioned positive or negative performance indicators.
24-02-2026
NRG Energy, Inc. filed a Form 8-K on February 24, 2026, under Item 2.02 disclosing Results of Operations and Financial Condition, and Item 9.01 providing Financial Statements and Exhibits. This is a multi-item filing standard for financial results announcements. No quantitative financial metrics, period-over-period changes, guidance, or other specific data points are disclosed in the provided filing information.
24-02-2026
Kiniksa Pharmaceuticals International, plc filed an 8-K on February 24, 2026, disclosing Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, guidance, or other financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed quantitative data available.
24-02-2026
Thermon Group Holdings, Inc. filed a Form 8-K on 2026-02-24 under Items 1.01 (Entry into a Material Definitive Agreement), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing representing a material event, but specific details of the agreement, transaction terms, financial impacts, or any metrics are NOT_DISCLOSED.
24-02-2026
Cipher Mining Inc. filed a multi-item Form 8-K on February 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This filing discloses financial results alongside governance changes, but specific details on operations, amendments, financial metrics, or performance are NOT_DISCLOSED. No quantitative data, period-over-period comparisons, or directional impacts are provided in the available information.
24-02-2026
CECO Environmental Corp filed an 8-K on 2026-02-24 reporting under Item 1.01 entry into a material definitive agreement, Item 7.01 Regulation FD Disclosure, and Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction value, financial impacts, or metrics are disclosed. This is a multi-item filing with no quantitative data or period-over-period comparisons provided.
24-02-2026
Repligen Corp filed an 8-K on February 24, 2026 (AccNo: 0001193125-26-065246), reporting Results of Operations and Financial Condition under Item 2.02 and including Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons were disclosed in the provided filing information. This represents a standard voluntary earnings disclosure with attached materials.
24-02-2026
24-02-2026
The company filed an 8-K on February 24, 2026 (AccNo: 0001104659-26-018824) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the key position affected, individuals involved, reasons for the change, appointment or resignation status, or any compensatory arrangements are disclosed. No quantitative data, financial metrics, or scheduled events are mentioned.
24-02-2026
Digi Power X Inc. filed a Form 8-K on February 24, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing represents a voluntary disclosure likely including material non-public information and attached exhibits such as a press release. No specific financial metrics, transactions, events, positive or negative changes, or quantitative data are disclosed in the provided filing summary.
24-02-2026
Fidelity National Information Services, Inc. filed a Form 8-K on February 24, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance data.
24-02-2026
Xilio Therapeutics, Inc. filed a Form 8-K on February 24, 2026 (AccNo: 0001193125-26-065234), reporting under Item 5.07 the submission of matters to a vote of security holders. No specific details on the shareholder meeting, proposals voted on, vote outcomes, or any numerical results are disclosed in the provided filing information. This appears to be a single-item, mandatory disclosure with no financial metrics, transaction values, or impacts mentioned.
24-02-2026
Willis Lease Finance Corp filed an 8-K on 2026-02-24 disclosing Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement). No specific details on the agreement, financial terms, parties, or impacts are provided in the filing summary. No quantitative metrics, positive or negative changes, or comparisons are mentioned.
24-02-2026
Twin Vee PowerCats, Co. filed an 8-K on 2026-02-24 disclosing entry into a material definitive agreement under Item 1.01, other events under Item 8.01, and financial statements and exhibits under Item 9.01. No specific details on the agreement, events, transaction value, financial impacts, or quantitative metrics are provided in the filing summary. No positive or negative performance metrics, period-over-period changes, or guidance revisions are mentioned.
- ·Multi-item 8-K filing (Items 1.01, 8.01, 9.01)
- ·Accession Number: 0001731122-26-000289
- ·File size: 669 KB
24-02-2026
Palvella Therapeutics, Inc. filed an 8-K on February 24, 2026 (AccNo: 0001193125-26-065308, Size: 12 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing involves a voluntary disclosure of potentially material non-public information with attached exhibits. No financial metrics, transactions, period-over-period comparisons, positive or negative changes, or other quantitative data are explicitly stated in the provided filing details.
24-02-2026
ENVIRI Corp filed a Form 8-K on February 24, 2026 (AccNo: 0000045876-26-000006), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are mentioned in the filing details provided. This appears to be a standard voluntary earnings release filing.
24-02-2026
Portillo's Inc. filed an 8-K on February 24, 2026 (AccNo: 0001871509-26-000011, Size: 4 MB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, period-over-period comparisons, guidance, or other quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no detailed results available.
24-02-2026
Diversified Healthcare Trust filed an 8-K on February 24, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits), with the filing size of 10 MB. No specific financial metrics, transactions, positive or negative changes, or operational details are disclosed in the provided filing summary. This appears to be a voluntary disclosure to ensure fair dissemination of material information, accompanied by exhibits.
24-02-2026
Atlanta Braves Holdings, Inc. filed a Form 8-K on February 24, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, quantitative data, or events are detailed in the filing summary provided. This appears to be a multi-item voluntary disclosure primarily for Reg FD compliance with attached exhibits.
24-02-2026
UFP Industries Inc filed a Form 8-K on 2026-02-24 under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits), marking a multi-item voluntary disclosure likely including attached exhibits such as a press release or presentation (file size 4 MB). No financial metrics, transactions, or specific events are detailed in the filing metadata. Critical content from exhibits is missing, limiting assessment of impacts.
- ·Accession Number: 0000912767-26-000010
24-02-2026
ESTABLISHMENT LABS HOLDINGS INC. filed an 8-K on February 24, 2026 (AccNo: 0001688757-26-000014), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, revenue, earnings, guidance, period-over-period changes, or other quantitative details are disclosed in the provided filing information. This is a multi-item informational filing with no directional data available.
24-02-2026
Clene Inc. filed a Form 8-K on February 24, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing summary. This is a multi-item informational filing with no quantified impacts or directional biases evident.
24-02-2026
Iovance Biotherapeutics, Inc. filed an 8-K on February 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, or quantitative data are disclosed in the provided filing information. All detailed revenue, earnings, guidance, or balance sheet impacts are NOT_DISCLOSED.
24-02-2026
FIRST HAWAIIAN, INC. filed an 8-K on February 24, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, timing, or any quantitative impacts are disclosed.
24-02-2026
Bayview Acquisition Corp filed an 8-K on 2026-02-24 under Item 3.01 providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing, in the context of a merger/acquisition event. No quantitative data, deal terms, financial metrics, parties involved, or other specific details are disclosed. Sector is not specified.
24-02-2026
Inhibitor Therapeutics, Inc. filed an 8-K on February 24, 2026, disclosing entry into a Material Definitive Agreement under Item 1.01. Item 9.01 includes Financial Statements and Exhibits. No financial metrics, transaction details, or impacts are disclosed.
24-02-2026
Kyverna Therapeutics, Inc. filed an 8-K on 2026-02-24 disclosing officer changes under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), other events under Item 8.01, and financial statements/exhibits under Item 9.01. Specific details including the key position affected, names of individuals, appointment or resignation status, reasons for change, and any quantitative data such as compensation amounts are NOT_DISCLOSED. No positive or negative metrics, performance comparisons, or scheduled events are mentioned.
24-02-2026
SCI Engineered Materials, Inc. filed an 8-K on 2026-02-24 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 reports financial statements and exhibits. No specific details, names, dates, financial impacts, or directional implications (positive or negative) are provided.
24-02-2026
NexPoint Residential Trust, Inc. filed an 8-K on February 24, 2026, disclosing Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No specific financial metrics, period-over-period comparisons, or performance details such as revenue, earnings, margins, or changes are mentioned. This is a standard voluntary filing for financial results with no quantified positive or negative impacts disclosed.
24-02-2026
Advantage Solutions Inc. filed a Form 8-K on 2026-02-24 reporting entry into a material definitive agreement under Item 1.01, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing, but specific details of the agreement, transaction value, financial impacts, or any positive/negative metrics are NOT_DISCLOSED. No quantitative data, period-over-period comparisons, or directional indicators are provided.
24-02-2026
Harmony Biosciences Holdings, Inc. filed an 8-K on February 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure typical for earnings releases, but specific financial metrics including revenue, earnings, guidance, or period-over-period changes are NOT_DISCLOSED in the provided information. No positive, negative, or flat performance indicators are detailed.
24-02-2026
Cadrenal Therapeutics, Inc. filed an 8-K on February 24, 2026 (AccNo: 0001213900-26-019606, size: 224 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or contents of the financial statements and exhibits are disclosed. This appears to be a multi-item informational filing with no quantified metrics or directional performance indicators provided.
24-02-2026
Playboy, Inc. filed a Form 8-K on 2026-02-24 disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative financial metrics are mentioned. This is a standard voluntary earnings-related disclosure without detailed performance data.
24-02-2026
Modular Medical, Inc. filed an 8-K on February 24, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 provides financial statements and exhibits. No specific transaction details, dollar values, terms, or financial impacts are disclosed.
24-02-2026
EQV Ventures Acquisition Corp. filed an 8-K on 2026-02-24 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger/acquisition, along with unregistered sales of equity securities (Item 3.02), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No specific transaction parties, deal size, valuation, or financial metrics are disclosed in the provided filing summary. This appears to be a standard SPAC business combination announcement without detailed terms.
24-02-2026
Golden Matrix Group, Inc. filed an 8-K on 2026-02-24 under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, or any quantitative data such as compensation amounts are disclosed in the provided filing information. No positive or negative metrics are mentioned.
24-02-2026
NightFood Holdings, Inc. filed an 8-K on February 24, 2026 (AccNo: 0001493152-26-007828, Size: 246 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary filing with no specific financial metrics, transactions, or events detailed in the provided information. Sector is not specified.
24-02-2026
Microbot Medical Inc. filed an 8-K on February 24, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details, financial metrics, transactions, or events are disclosed in the provided filing summary. This appears to be a voluntary informational filing with attached exhibits.
24-02-2026
HeartCore Enterprises, Inc. filed a Form 8-K on February 24, 2026, under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details on the nature of the disclosures, events, financial statements, or exhibits are provided in the filing summary. This is a multi-item informational filing with no quantified metrics or directional impacts disclosed.
24-02-2026
Playboy, Inc. filed an 8-K on February 24, 2026, disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, elections of directors, appointments of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included with the filing. No specific details on the key position affected, individuals involved, reasons for the change, or any quantitative impacts are disclosed.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 111 filings
🇺🇸 More from United States
View all →March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC
March 24, 2026
US Corporate Distress Financial Stress SEC Filings — March 24, 2026
US Corporate Distress Financial Stress SEC Filings